Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AP-1 and antidepressant action

Sep. 1, 2020

Blood substitution therapy expands therapeutic time window for stroke

Aug. 31, 2020

GNE-565: a Nav1.7 inhibitor with oral activity in a mouse model of Nav.17-associated pain

Aug. 28, 2020

New neurotensin receptor type 2 agonists patented by Socpra Sciences Sante et Humaines SEC

Aug. 28, 2020

Synthetic synaptic protein restores neuronal connections

Aug. 28, 2020

MK-4710: a new potent, selective, brain-penetrant M4R PAM suitable for clinical development

Aug. 27, 2020

Lilly discovers KCNQ2/3 channel activators

Aug. 27, 2020

Topline data presented from phase II ELEKTRA study of soticlestat

Aug. 26, 2020

BIIB-091: a potent, highly selective BTK inhibitor for the treatment of multiple sclerosis

Aug. 26, 2020

Bristol-Myers Squibb discovers TYK2 inhibitors

Aug. 25, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...